Digistain

Digistain is a biotechnology company developing MHRA-cleared diagnostic technology for predicting breast cancer recurrence risk.

The platform uses infrared spectrometry to generate spectroscopic signatures from tumour biopsy tissue, with AI analysis producing a personalised prognostic score indicating the likelihood of disease recurrence over ten years.

The technology is designed as a faster and lower-cost alternative to transcriptomic profiling methods, enabling patient stratification for adjuvant chemotherapy decisions.